Introduction
============

Amikacin Inhale (NKTR-061, BAY41-6551) is a drug-device combination in clinical development for adjunctive treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia. The product uses a proprietary vibrating mesh nebulizer system (PDDS Clinical) with amikacin sulfate formulated for inhalation (3.2 ml of 125 mg/ml amikacin solution) for a 10-day twice-daily course of therapy. It is designed for use with two delivery systems: one system for intubated patients (On-vent; Figure [1](#F1){ref-type="fig"}), and a second Handheld (HH) system for patients who are extubated before completing the course of therapy (Figure [2](#F2){ref-type="fig"}). We investigated *in vitro*the amikacin lung dose delivered by PDDS Clinical.

![**On-vent system with brown blinder shell for clinical trials**.](cc12019-1){#F1}

![**Handheld system with brown blinder shell for clinical trials**.](cc12019-2){#F2}

Methods
=======

An estimated lung dose (ELD) for On-vent setting was measured *in vitro*after collecting aerosolized amikacin from a filter at the end of an endotracheal tube during ventilation. The ELD for the HH device was calculated from the fine particle fraction (FPF \<5 µm) post-mouthpiece, multiplied by the *in vitro*delivered dose post-mouthpiece. FPF \<5 µm reflects lung deposition observed during phase 2 clinical trials \[[@B1]\]. Eighty-one nebulizers with volume median diameter (VMD) of 4.4 ± 0.5 µm and output rates of 0.23 ± 0.10 ml/minute were tested for each system. Delivered dose data were fit to the independent variables (that is, VMD and output rates) using a least-squares fit with 95% confidence limits.

Results
=======

Total percentage recoveries for On-vent and HH test runs were between 85% and 115% of the nominal dose. The mean ELDs were 50 ± 9% (On-vent) and 49 ± 11% (HH) of the nominal dose. Nebulizers with longer dosing times and lower VMDs had higher ELD values for both delivery systems.

Conclusion
==========

The results support the use of the PDDS Clinical with either system to administer aerosolized amikacin with high efficiency and no dose adjustment is required when switching from the On-vent to the HH system for extubated patients.
